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WHAT THIS PAPER ADDS
 Vitamin D receptors have awide tissue distribution including the vascular wall. This suggests that vitamin D status might play a role
in the pathogenesis of arterial disease. The current study shows a high prevalence of vitamin D deﬁciency in patients with occlusive
as well as in those with aneurysmatic arterial disease. The study further demonstrates a strong association between low vitamin D
status and the severity of atherosclerosis. Since this relationship was independent of traditional cardiovascular risk factors and
irrespective of the type of arterial disease, these data suggest a direct effect of vitamin D deﬁciency on the arterial wall.a r t i c l e i n f o
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Objectives: The aim of this study was to assess the vitamin D status in patients with occlusive or
aneurysmatic arterial disease in relation to clinical cardiovascular risk proﬁles and markers of athero-
sclerotic disease.
Methods:We included 490 patients with symptomatic peripheral arterial disease (PAD, n ¼ 254) or aortic
aneurysm (n ¼ 236). Cardiovascular risk factors and comorbidities carotid intimaemedia thickness
(CIMT), ankleebrachial index (ABI), serum high-sensitive C-reactive protein (hs-CRP) and vitamin D
were assessed. Patients were categorised into severely (25 nmol l1) or moderately (26e50 nmol l1)
vitamin D deﬁcient, vitamin D insufﬁcient (51e75 nmol l1) or vitamin D sufﬁcient (>75 nmol l1).
Results: Overall, 45% of patients suffered frommoderate or severe vitamin D deﬁciency. The prevalence of
vitamin D deﬁciency was similar in patients with PAD and those with an aortic aneurysm. Low levels of
vitamin D were associated with congestive heart failure and cerebrovascular disease. Adjusting for
clinical cardiovascular risk factors, multivariable regression analyses showed that low vitamin D status
was associated with higher CIMT (P ¼ 0.001), lower ABI (P < 0.001) and higher hs-CRP (P ¼ 0.022).
Conclusions: The current study shows a strong association between low vitamin D status and arterial
disease, independent of traditional cardiovascular risk factors and irrespective of the type of vascular
disease, that is, occlusive or aneurysmatic disease.
 2012 Published by Elsevier Ltd on behalf of European Society for Vascular Surgery.Several large epidemiological studies have concluded that
vitamin D deﬁciency is associated with excess mortality.1,2 It is
becoming increasingly clear that vitamin D has a much broader
range of actions in the human body in addition to its well-known
effects on calcium homeostasis and bone metabolism. There ist of Vascular Surgery, Suite
lands. Tel.: þ31 10 703 1810;
Verhagen).
Elsevier Ltd on behalf of Europeaaccumulating evidence that vitamin D deﬁciency has important
extraskeletal effects, including the cardiovascular system.3,4 Several
clinical studies have reported a high prevalence of vitamin D deﬁ-
ciency in patients with peripheral arterial disease (PAD),5 coronary
artery disease6 and stroke,7 as well as the association of vitamin D
deﬁciency with cardiovascular mortality.2,8,9 Furthermore, low
vitamin D status is related to major cardiovascular risk factors, such
as hypertension, obesity and diabetes mellitus.4,10,11
The aforementioned studies suggest that vitamin D deﬁciency
promotes atherosclerosis.4,12 However, it is not knownwhether thisn Society for Vascular Surgery.
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of a vitamin D deﬁciency-associated increase in established
cardiovascular risk factors. It is also unclear whether the severity of
arterial disease is related to the severity of vitamin D deﬁciency.
Furthermore, it is not known whether patients with aneurysmatic
arterial disease also display vitamin D deﬁciency.
To answer these questions, we assessed the vitamin D status in
a large population of patients with occlusive or aneurysmatic
arterial disease, and related this to clinical cardiovascular risk
proﬁles as well as to markers for the severity of arterial disease.
Materials and Methods
Study population
The study population consisted of patients with PAD or aortic
aneurysmatic disease treated between 2004 and 2011 in the Eras-
mus University Medical Center in Rotterdam, the Netherlands.
Patients with PAD were deﬁned as having symptomatic athero-
sclerotic lower extremity arterial disease with an ankleebrachial
index (ABI) of 0.9. Patients with aortic aneurysms were deﬁned
as having an aortic diameter >30 mm. Common carotid artery
intimaemedia thickness (CIMT), ABI and high-sensitive C-reactive
protein (hs-CRP) were routinely measured in all vascular-surgery
patients. Patients with routinely measured serum vitamin D
levels at the vascular outpatient clinic were included, whereas
patients using vitamin D supplementation were excluded from this
study. The study complies with the Declaration of Helsinki and was
approved by the Institutional Review Board.
Baseline characteristics
A detailed history was obtained from every patient, including
traditional risk factors such as age, sex, hypertension (deﬁned as
a blood pressure 140/90 mmHg in non-diabetics, 130/80 mmHg
in diabetics or use of anti-hypertensive medication), hyper-
cholesterolaemia (deﬁned as a low-density lipoprotein (LDL)
cholesterol 3.5 mmol l1 or use of lipid-lowering medication),
chronic obstructive pulmonary disease (COPD; deﬁned as a history
of COPD or stage 1 according to the Global Initiative for
Obstructive Lung Disease (GOLD) classiﬁcation), diabetes mellitus
(deﬁned as a fasting plasma glucose 7.0 mmol l1, non-fasting
glucose 11.1 mmol l1 or use of anti-diabetic medication) and
smoking status. Furthermore, the atherosclerotic and cardiac risk
factors as embedded in the Revised Cardiac Risk (RCR) index were
obtained.13 The RCR index includes congestive heart failure
(deﬁned as a history of congestive heart failure), ischaemic heart
disease (deﬁned as a history of myocardial infarction, coronary
revascularisation or the presence of pathologic Q-waves on the
electrocardiogram), cerebrovascular disease (deﬁned as a history of
ischaemic/haemorrhagic stroke or transient ischaemic attack),
kidney disease (deﬁned as a serum creatinine 2.0 mg dl1) and
insulin-dependent diabetes mellitus. The use of prescription
medications was recorded and included statins, beta-blockers,
rennineangiotensinealdosterone system (RAAS) inhibitors and
diuretics.
Atherosclerotic markers
The severity of atherosclerotic disease was assessed by
measurements of the CIMT, ABI and hs-CRP. The CIMT was
measured using the guidelines from the ‘Mannheim Carotid
IntimaeMedia Thickness Consensus’.14,15 Several measurements
from the left and the right common carotid artery were made. The
highest CIMT value was used for analysis, while measurements ofplaques (deﬁned as a focal structure encroaching into the arterial
lumen of at least 0.5 mm)14 were excluded from analysis. The ABI
was measured at rest using a portable counter-top Doppler 8-MHz
vascular probe (Imexdop CT þ Vascular Doppler; Nicolet Vascular,
Madison,WI, USA). The ABI was calculated by dividing the higher of
the right and left systolic ankle pressures (posterior tibial or dorsal
pedal artery) by the highest systolic brachial blood pressure,
according to the TransAtlantic Inter-Society Consensus for
Management of PAD (TASC) guidelines.16 Serum hs-CRP was
measured using immunochemistry (Beckman Coulter, Woerden,
the Netherlands).
Vitamin D measurements
Serum vitamin D was measured in fresh blood samples using
a 25-hydroxyvitamin D radioimmunoassay (Diasorin Inc., Still-
water, MN, USA). Within-run coefﬁcient of variation (CV) was
8.6e12.5% and total imprecision CV was 8.2e11.0%. Patients were
categorised into four groups based on commonly used cut-off val-
ues:17e19 severely (25 nmol l1) or moderately (26e50 nmol l1)
vitamin D deﬁcient, vitamin D insufﬁcient (51e75 nmol l1) or
vitamin D sufﬁcient (>75 nmol l1). To convert nanomolar to
nanogram per millilitre, one should divide by 2.496.
Statistical analysis
Dichotomous data are described as counts and percentages.
Continuous variables are described as mean  standard deviation
(SD), or median and interquartile ranges (IQRs) in the case of non-
Gaussian distribution. Categorical data were compared using chi-
square tests. Continuous variables were compared using analysis
of variance (ANOVA), or KruskaleWallis tests as appropriate. Linear
univariable and multivariable regression analyses were performed
in separate models using CIMT, ABI or the natural logarithm of hs-
CRP as dependent variable. Vitamin D concentrations per
10 nmol l1 was used as independent variable and adjustments
were made for age, gender, congestive heart failure, ischaemic
heart disease, cerebrovascular disease, renal function by estimated
glomerular ﬁltration rate (eGFR), diabetes mellitus, COPD, hyper-
tension, smoking and type of arterial disease. To address the
seasonal ﬂuctuation of vitamin D levels, further adjustments were
made for calendar season of vitamin D measurement. For all tests,
a P-value <0.05 (two-sided) was considered signiﬁcant. All anal-
yses were performed using PASW (Predictive Analytics Software)
version 17.0 statistical software (SPSS Inc., Chicago, IL, USA).
Results
A total of 490 patients were included in the study. As many as
254 patients (51.8%) were diagnosed with PAD of the lower
extremities and 236 patients (48.2%) were diagnosed with
a thoracic and/or abdominal aortic aneurysm (AAA). The mean age
of the populationwas 6711 years and the average value of vitamin
D concentration was 57  93 nmol l1, as presented in Table 1. A
total of 62 patients (12.7%) were severely vitamin D deﬁcient, 160
patients (32.7%) were moderately deﬁcient, 138 patients (28.2%)
were vitamin D insufﬁcient and 130 patients (26.5%) had sufﬁcient
vitamin D levels. There were no differences between patients with
PAD and those with an aortic aneurysm with regard to the
frequencies of vitamin D deﬁciency (P ¼ 0.258, Fig. 1) or the mean
vitaminD concentration (5731 and 59.2 27 nmol l1, P¼ 0.390).
Mean ABI in the patients with aneurysmatic disease was 0.88 and
47% of these patients had an ABI 0.9. No signiﬁcant differences in
vitamin D concentration were found between AAA patients with
normal ABI or low ABI (mean 63 vs. 55 nmol l1, P¼ 0.066). Further,
Table 1
Baseline characteristics according to vitamin D status.
Total population Vitamin D status P-value for
trend
Severely deﬁcient Moderately deﬁcient Insufﬁcient Sufﬁcient
25 nmol/L 26e50 nmol/L 51e75 nmol/L >75 nmol/L
n ¼ 490 n ¼ 62 n ¼ 160 n ¼ 138 n ¼ 130
Vitamin D level (nmol/L), mean(SD) 57  93 17  6 39  7 62  7 96  19 e
Baseline characteristics
Male gender (%) 355 (72.4) 42 (67.7) 114 (71.3) 111 (80.4) 88 (67.7) 0.083
Age (yearsSD) 66.8  10.7 64.311.6 66.9  11.2 67.8  9.6 66.7  10.6 0.212
Body mass index (kg/m2), mean(SD) 26.4  4.4 26.1  5.3 26.4  4.6 26.8  4.2 26.0  4.0 0.495
eGFR (ml/min/1.73 m2), mean(SD) 78.32  26.29 86.07  30.75 75.18  28.74 78.46  23.48 78.35  22.97 0.053
Type of arterial disease
Peripheral arterial disease (%) 254 (51.8) 39 (62.9) 81 (50.6) 72 (52.1) 62 (47.6) 0.258
Thoracic and/or abdominal aortic aneurysm (%) 236 (48.2) 23 (37.1) 79 (49.4) 66 (47.8) 68 (52.3)
Cardiovascular diseases
Congestive heart failure (%) 40 (8.1) 12 (19.3) 16 (10.0) 6 (4.3) 6 (4.6) 0.001
Ischaemic heart disease (%) 185 (37.7) 27 (43.5) 69 (43.1) 50 (36.2) 39 (30.0) 0.112
Cerebrovascular disease (%) 85 (17.3) 13 (20.9) 35 (21.8) 27 (19.5) 10 (7.6) 0.009
Cardiovascular risk factors
Kidney disease (2.0 mg/dl) 46 (9.1) 4 (6.4) 22 (13.7) 11 (7.9) 9 (6.9) 0.103
Diabetes mellitus (%) 100 (20.4) 20 (32.2) 32 (20.0) 25 (18.1) 23 (17.6) 0.103
Hypertension (%) 329 (67.1) 41 (66.1) 105 (65.6) 103 (74.6) 80 (61.5) 0.152
Hypercholesterolaemia (%) 455 (92.8) 58 (93.5) 152 (95.0) 126 (91.3) 119 (91.5) 0.573
Smoking e current (%) 209 (42.6) 36 (58.0) 71 (44.3) 62 (44.9) 40 (30.7) 0.014
Smoking e ever (%) 379 (77.3) 54 (87.0) 120 (75.0) 110 (79.7) 95 (73.0) 0.129
COPD (%) 171 (34.8) 22 (35.4) 59 (36.8) 43 (31.1) 47 (36.1) 0.691
RCR index
RCR score, mean(SD) 1.16  1.01 1.45  1.14 1.27  1.10 1.11  0.84 0.93  0.97 0.004
0e1 risk factors (%) 333 (67.9) 36 (58.0) 100 (62.5) 98 (71.1) 99 (76.1) 0.001
2 risk factors (%) 105 (21.4) 14 (22.5) 38 (23.7) 33 (23.9) 20 (15.3)
3 risk factors (%) 52 (10.6) 12 (19.3) 22 (13.7) 7 (5.0) 11 (8.4)
Medication
Statins (%) 411 (83.8) 54 (87.0) 139 (81.2) 112 (81.1) 106 (81.5) 0.548
Beta-blockers (%) 383 (78.1) 50 (80.6) 124 (77.5) 110 (79.7) 99 (76.1) 0.903
RAAS inhibitors (%) 235 (47.9) 32 (51.6) 78 (48.7) 71 (51.4) 54 (41.5) 0.384
Diuretics (%) 122 (24.8) 14 (22.5) 44 (27.5) 37 (26.8) 27 (20.7) 0.536
Antiplatelets (%) 327 (66.7) 49 (79.0) 99 (61.8) 92 (66.6) 87 (66.9) 0.124
Abbreviations: eGFR; estimated glomerular ﬁltration rate, COPD; chronic obstructive pulmonary disease, RCR index; Revised Cardiac Risk index, RAAS inhibitors; renin-
angiotensin system inhibitors.
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the overall population, no differences between patients with PAD
and aneurysms were observed, as presented in Fig. 2.
Cardiovascular comorbidities
Patient groups with decreasing vitamin D levels had an
increasing prevalence of congestive heart failure (P ¼ 0.001),
cerebrovascular disease (P ¼ 0.009) and were more frequent
current smokers (P ¼ 0.014), as presented in Table 1. Overall high-
risk cardiovascular proﬁles were signiﬁcantly associatedwith lower
vitamin D levels, as illustrated by a stepwise increase in RCR scores
for groups with increasing vitamin D deﬁciency (P ¼ 0.004).Figure 1. Prevalence of vitamin D deﬁciency according to type of arterial disease.Atherosclerotic markers
The mean (SD) CIMT in all patients was 0.97  0.31 mm and
a stepwise decrease was observed from 1.06  0.37 mm in patients
with severe vitamin D deﬁciency to 0.90  0.27 in patients with
sufﬁcient vitamin D levels (P ¼ 0.007), as presented in Table 2. The
mean ABI was 0.70  0.26 and increased stepwise in each group
from 0.56  0.28 in patients with severe vitamin D deﬁciency to
0.77  0.24 in patients with sufﬁcient vitamin D levels (P < 0.001).
Furthermore, median hs-CRP in all groups was 4.3 mg l1 (IQR:
2.2e7.8 mg l1). High concentrations of hs-CRP were especiallyFigure 2. Seasonal variation in vitamin D deﬁciency according to type of arterial
disease.
Table 2
Atherosclerotic markers according to vitamin D status.
Atherosclerotic markers Vitamin D status P-value for trend
Total population Severely deﬁcient Moderately deﬁcient Insufﬁcient Sufﬁcient
25 nmol/L 26e50 nmol/L 51e75 nmol/L >75 nmol/L
CIMT (mm) (mean  SD) 0.97  0.31 1.06  0.37 1.01  0.34 0.94  0.27 0.90  0.27 0.007
ABI (mean  SD) 0.70  0.26 0.56  0.28 0.68  0.25 0.72  0.26 0.77  0.24 <0.001
hs-CRP (mg/L) [IQR] 4.3 [2.2e7.8] 7.5 [2.5e12.7] 4.0 [2.3e7.9] 3.8 [1.9e6.8] 4.8 [2.2e7.8] 0.040
Abbreviations: CIMT; common carotid intima-media thickness, ABI; ankle-brachial index, hs-CRP; high-sensitive C-reactive protein.
K.M. van de Luijtgaarden et al. / European Journal of Vascular and Endovascular Surgery 44 (2012) 301e306304observed in patients with severe vitamin D deﬁciency with
a median of 7.5 mg l1 (2.5e12.7 mg l1) (P ¼ 0.040).
Multivariable linear regression analyses were performed to
determine the association between vitamin D concentration and
CIMT, ABI and hs-CRP independently of clinical risk factors.
Signiﬁcant associations for vitamin D concentration per 10 nmol l1
were observed for CIMT (beta 0.017 mm, 95% conﬁdence interval
(95%CI): e0.027:e0.007, P ¼ 0.001), ABI (beta 0.015, 95%CI:
0.007:0.022, P < 0.001) and hs-CRP (beta 0.047 mg l1, 95%CI:
e0.086:e0.007, P ¼ 0.022) (Table 3).
Discussion
The current study shows a strong association between low
vitamin D status and the severity of arterial disease, independent of
traditional cardiovascular risk factors and irrespective of the type of
vascular disease, i.e. occlusive or aneurysmatic disease.
Vitamin D3 is synthesised in the skin from cholesterol under the
action of ultraviolet B light.3 Furthermore, vitamin D can be
ingested as cholecalciferol (vitamin D3) or ergocalciferol (vitamin
D2). Vitamin D is subsequently converted to 25-hydroxyvitamin D
(calcidiol) in the liver or stored in adipose tissue. In the kidneys, 25-
hydroxyvitamin D is converted to 1,25-dihydroxyvitamin D (calci-
triol), which is the biologically active form of vitamin D.3 The blood
concentration of 25-hydroxyvitamin D reﬂects the dietary intake of
vitamin D2 or D3 and the amount of vitamin D3 produced in the
skin, and is considered as the best indicator of vitamin D storage.17
As there is still some debate on the best classiﬁcation of vitamin D
status,17e20 we used a currently proposed vitamin D classiﬁcation
including clinical relevant cut-off values to describe vitamin D
status in our patient cohort.
The observed prevalence of vitamin D deﬁciency (i.e.,
50 nmol l1) of 45% in patients with arterial disease is comparable
to previous reports on vitamin D levels in patients with PAD.21e24
As vitamin D deﬁciency has been identiﬁed as an independentTable 3
Multivariable linear regression models for associations between vitamin D and
atherosclerotic markers.
Atherosclerotic
markers
n Beta for
vitamin Db
95%CI for Beta P-value
CIMT 439 Unadjusted 0.019 0.029 : 0.009 <0.001
Adjusteda 0.017 0.027 : 0.007 0.001
ABI 365 Unadjusted 0.017 0.008 : 0.026 <0.001
Adjusteda 0.015 0.007 : 0.022 <0.001
hs-CRP 391 Unadjusted 0.044 0.082 : 0.005 0.027
Adjusteda 0.047 0.086 : 0.007 0.022
Abbreviations: CIMT; common carotid intima-media thickness, ABI; ankle-brachial
index, hs-CRP; high-sensitive C-reactive protein.
a Adjusted for: age, gender, congestive heart failure, ischaemic heart disease,
cerebrovascular disease, renal function using eGFR, diabetes mellitus, chronic
obstructive pulmonary disease, hypertension, smoking, type of arterial disease and
calendar season of 25-hydroxyvitamin D measurement.
b Vitamin D per 10 nmol/L.risk factor for mortality,1,2 the question arises if and how vitamin D
deﬁciency is related to the occurrence of cardiovascular events. In
line with previous reports,7,25 we found that vitamin D deﬁciency is
associated with the occurrence of congestive heart failure and
cerebrovascular disease in univariable analyses. In addition, as
compared to patients with sufﬁcient vitamin D levels, patients with
severe vitamin D deﬁciency had a signiﬁcantly higher RCR index,
a well-known predictor of postoperative cardiovascular events in
patients undergoing non-cardiac surgery.13
Next, we attempted to identify how vitamin D status is related to
the severity of arterial disease. We observed a strong association
between vitamin D and the atherosclerotic markers, CIMT and ABI.
The CIMT and ABI provide information about the progression of
atherosclerosis. In previous reports, Flu et al. showed the prog-
nostic value of CIMT and ABI, independent of the RCR index.26,27
Targher et al. observed a similar association between vitamin D
deﬁciency and CIMT in patients with diabetes mellitus,28 and Reis
et al. reported a signiﬁcant association between vitamin D deﬁ-
ciency and the internal, rather than the common, CIMT.29 To our
knowledge, only two other studies reported ABI measurements in
patients with vitamin D deﬁciency.5,30 Although both studies
reported mild associations, our study clearly shows the stepwise
decrease in ABI per vitamin D deﬁciency category, and a signiﬁcant
correlation in multivariable linear regression models. In addition,
whereas other studies reported varying results regarding CRP and
vitamin D deﬁciency,30e32 the current study shows that serum hs-
CRP levels are elevated in patients with severe vitamin D deﬁciency.
In contrast to previous studies, we found that vitamin D deﬁ-
ciency was not related to hypertension, obesity, diabetes and dys-
lipidaemia. Furthermore, the correlation between low vitamin D
status and markers of atherosclerotic severity was independent of
cardiovascular risk factors.
Interestingly, the association between low vitamin D status and
the severity of arterial disease was independent of type of vascular
disease. To our knowledge, this relationship between vitamin D
status and aneurysm formation has thus far not been reported in
humans. Although aortic aneurysms have traditionally been
attributed to atherosclerosis, there is increasing epidemiological,
biochemical and genetic evidence that aneurysmal arterial disease
is different from occlusive atherosclerotic disease, a common
denominator being ageing of the arterial wall.
Taken together, the data in the current study suggest that the
relationship between low vitamin D status and arterial disease is
mediated by an independent effect of vitamin D deﬁciency on the
arterial wall. Vitamin D receptors are not exclusively detected in the
bone and mineral pathway, but have a wide tissue distribution,
including vascular smooth-muscle cells and vascular endothelial
cells.17 The diverse physiologic actions of vitamin D on the vascular
wall include reduction of smooth muscle-cell proliferation,33
reduction of macrophage secretion of pro-inﬂammatory cytokines
interleukin-6 (IL-6) and tumour necrosis factor-a (TNF-a) and
increased secretion of the anti-inﬂammatory cytokine IL-10, and
therefore reducing the state of vascular inﬂammation.34e36 In an
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vitamin D3 reduces the formation of atherosclerotic plaques by the
suppression of proatherogenic T lymphocytes.37 In addition, low
circulating levels of vitamin D have been associated with endo-
thelial dysfunction in humans.38,39 Furthermore, it has previously
been reported that people with vitamin D deﬁciency have
increased vascular calciﬁcation, a sign of advanced atheroscle-
rosis,40,41 as well as increased aortic stiffness.42 These vitamin D-
related effects all promote arterial disease.4,12 Experimental studies
provide increasing evidence that factors regulating mineral ion
homeostasis, such as vitamin D, affect the ageing process, including
vascular ageing.43
There are several limitations that need to be considered. Due
to the nature of this study, it remains uncertain whether the
association between low vitamin D status and arterial disease is
causal, or whether it is just a bystander. Furthermore, several
potentially confounding factors could have inﬂuenced our anal-
yses, the most important ones being race, diet and sunlight
exposure. As our study population consisted mostly of Cauca-
sians, race was not a factor in our analyses. Moreover, as lower
vitamin D levels are observed in non-Caucasian populations, the
true prevalence of vitamin D deﬁciency in PAD patients may
actually have been underestimated. The inﬂuence of low dietary
intake, thereby not only reducing vitamin D but also other
nutrients, was not taken into account in this study. However, low
vitamin D in the European population is mainly caused by low
sunlight exposure rather than diet.17,44 Therefore, in the multi-
variable models we corrected for the season of vitamin D
measurement to minimise confounding by seasonal variations in
sunlight exposure.
In conclusion, this study demonstrates that low vitamin D
status is a risk factor for the severity of arterial disease, inde-
pendent of traditional cardiovascular risk factors and irrespective
of the type of vascular disease, i.e. occlusive or aneurysmatic
disease. It might be hypothesised that primary and secondary
preventive strategies to reduce vascular disease should focus on
vitamin D status, in addition to blood-pressure reduction, lipid and
glucose control, weight loss and lifestyle changes. A beneﬁcial
effect of vitamin D supplementation on blood-pressure reduction
has been demonstrated in several clinical trials.45,46 Although
improving vitamin D status might be a promising public-health
strategy to reduce cardiovascular disease and improve
survival,47,48 there is still much debate about the requirement
levels of vitamin D in relation to extra-skeletal outcomes.20
Further large-scale, randomised clinical trials are needed to test
the effects of vitamin D on cardiovascular disease and to further
elucidate the biology of vitamin D on the arterial wall.Funding
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